LQDA (Liquidia) Long-Term Debt : $97.37 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Liquidia Long-Term Debt?

Liquidia's Long-Term Debt for the quarter that ended in Dec. 2024 was $97.37 Mil.

Liquidia's quarterly Long-Term Debt stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($97.37 Mil).

Liquidia's annual Long-Term Debt increased from Dec. 2022 ($19.88 Mil) to Dec. 2023 ($43.42 Mil) and increased from Dec. 2023 ($43.42 Mil) to Dec. 2024 ($97.37 Mil).

Liquidia Long-Term Debt Historical Data

The historical data trend for Liquidia's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Long-Term Debt Chart

Liquidia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

10.29

10.41

19.88

43.42

97.37

Liquidia Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															43.42	-	-	-	97.37

Liquidia (NAS:LQDA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Liquidia Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Liquidia's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Liquidia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

LT4:Germany

Address

419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560

Website

https://www.liquidia.com

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Executives

Jason Adair	officer: V.P. Crp Dvlpmnt and Strtgy	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Rajeev Saggar	officer: Chief Medical Officer	419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Scott Moomaw	officer: SVP, Commercial	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta	officer: Chief Financial Officer	7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler	officer: General Counsel	P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Roger Jeffs	director
Paul B Manning	director, 10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Caligan Partners Lp	director, 10 percent owner, other: See Remarks	515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe	officer: Chief Operations Officer	C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Arthur S Kirsch	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson	10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
Raman Singh	director	C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Katherine Rielly-gauvin	director	419 DAVIS DRIVE, MORRISVILLE NC 27560
Stephen M Bloch	director	285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880
Joanna Horobin	director	215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142